Alder biopharmaceuticals inc (ALDR)
Income statement / TTM
Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenues
Collaboration and license agreements

0

0

0

683

0

0

-

-

0

-

-

-

0

-

-

-

-

-

54,705

53,093

19,019

18,979

18,796

0

0

0

Operating expenses
Cost of sales

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

215,956

234,649

239,108

219,408

223,803

236,261

252,902

249,942

227,245

195,802

132,760

112,607

105,968

86,223

69,611

57,970

42,165

37,454

33,439

29,778

31,653

30,421

31,883

0

0

0

General and administrative

90,141

80,419

47,474

44,486

42,037

39,674

38,102

35,163

33,166

30,084

26,148

23,543

21,622

19,086

16,718

15,333

14,173

12,979

12,462

11,407

10,108

9,013

7,674

0

0

0

Total operating expenses

306,097

315,068

286,582

264,830

266,776

277,554

292,623

285,788

261,094

225,999

159,021

136,263

127,703

105,309

86,329

73,303

56,338

50,433

45,901

41,185

41,761

39,434

39,557

0

0

0

Gain on license of clazakizumab

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-306,097

-315,068

-286,582

-263,894

-265,840

-275,935

-291,004

-285,105

-260,411

-224,836

-157,858

-135,100

-126,540

-105,309

-86,329

-66,867

-11,118

-510

8,804

11,908

-22,742

-20,455

-20,761

0

0

0

Other income (expense)
Interest income

9,191

9,232

8,909

7,443

5,748

3,653

2,495

2,159

1,945

2,036

1,966

1,814

1,513

1,058

702

395

165

100

44

37

28

35

54

0

0

0

Interest expense

19,459

19,172

17,185

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency gain (loss)

-

-

-

487

-

-

223

38

-224

-257

-349

-422

-102

0

-

0

0

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

0

Change in fair value of derivative liability

-2,828

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Total other income (expense), net

-11,257

-12,264

-9,625

-6,401

-2,916

1,069

2,768

2,246

1,893

1,951

1,789

1,666

1,149

1,129

859

620

514

160

104

241

150

0

-

0

0

-

Net loss before equity in net loss of unconsolidated entity

-317,354

-327,332

-296,207

-270,295

-268,756

-274,866

-288,236

-282,859

-258,518

-222,885

-156,069

-134,266

0

0

-

0

-

-

-

-

-

-

-

-

-

-

Equity in net loss of unconsolidated entity

-

-

-222

-402

-586

-716

-643

-557

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-317,354

-327,332

-296,429

-270,697

-269,342

-275,582

-288,879

-283,413

-258,982

-223,219

-156,254

-133,528

-125,391

-104,180

-85,470

-66,247

-10,604

-350

8,908

11,975

-22,580

-20,326

-20,613

0

0

0

Deemed dividends on convertible preferred stock attributable to accretion of beneficial conversion feature

-

-

29,460

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Dividends on convertible preferred stock

5,451

6,273

6,045

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss applicable to common stockholders

-322,805

-333,605

-331,934

-304,821

-302,187

-306,125

-288,879

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share - basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.93

-

-

-

-6.05

-

-

Net income (loss) per share - diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.88

-

-

-

-6.05

-

-

Weighted average number of common shares used in net income (loss) per share - basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30,805

-

-

-

976

-

-

Weighted average number of common shares used in net income (loss) per share - diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,513

-

-

-

976

-

-

Net loss per share applicable to common stockholders - basic and diluted

-0.72

-1.63

-1.19

-0.91

-1.04

-1.73

-0.56

-0.92

-1.48

-1.99

-0.98

-0.70

-0.79

-0.76

-0.63

-0.62

-0.46

-0.40

-

-

-0.40

-5.38

-

-

-5.27

-5.89

Weighted average number of common shares used in net loss per share - basic and diluted

83,479

73,056

68,352

68,232

67,966

67,844

68,039

64,526

50,427

50,395

50,365

50,226

49,284

43,753

43,756

43,525

38,162

36,903

-

-

18,556

1,002

-

-

976

964